Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

This was the stock's fourth consecutive day of losses.

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology. With over 25 years in healthcare ...

The stock's rise snapped a five-day losing streak.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences UK & Ireland, said: "Gilead welcomes the announcement from NHS England about its commitment to make England one of the first countries to eliminate hepatitis C. This is an ambition ...

If you’re on the fence about investing in Gilead Sciences, Inc., BeiGene or Ltd. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg Pharma plc, which was announced on January ...

After hours: 7:54:57 p.m. EST Loading Chart for GILD ...